ARCA receives European Patent for bucindolol based treatment for heart failure ARCA biopharma.

We are obviously pleased with the European Patent Office’s issuance of this patent, which we believe will expand our pharmacogenetic intellectual residence protection around bucindolol and, if approved for advertising, provide Gencaro marketplace exclusivity in the designated countries into 2025, said Michael R. Bristow, Chief and President Executive Officer of ARCA.. ARCA receives European Patent for bucindolol based treatment for heart failure ARCA biopharma, Inc. , a biopharmaceutical company developing genetically-targeted treatments for heart failing and other cardiovascular diseases, today announced that the European Patent Office has issued a patent on ways of treating heart failing patients with bucindolol based on genetic targeting.Influenza pandemics have occurred 3 x throughout modern background with deadly consequences. The 1st, the Spanish Flu of 1918, caused even more deaths than World War I. Unlike additional avian flu vaccines, which are developed from live infections partially, the vaccine uses a virus-like particle, or VLP, that is recognized by the immune system as a real virus but lacks genetic info to reproduce, making it a safer alternate for a human vaccine potentially. Given the evolving character of H5N1, the vaccine was designed to encode genes for three influenza viral proteins to offer enhanced protection against feasible fresh strains of the virus.